<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52052">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428543</url>
  </required_header>
  <id_info>
    <org_study_id>2013-000268-27</org_study_id>
    <nct_id>NCT02428543</nct_id>
  </id_info>
  <brief_title>Ponatinib for FLT3-ITD Acute Myelogenous Leukemia</brief_title>
  <acronym>PONATINIB-AML</acronym>
  <official_title>A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is part of a joint ALFA and GOELAM strategy aiming to improve the survival of
      patients with newly diagnosed Acute Myeloid Leukemia (AML) aged 18-70 years. The basis of
      this strategy is to evaluate intensified conventional chemotherapy and targeted drugs in
      selected disease-risk subgroups of adult patients with non promyelocytic AML. Participation
      will be proposed to almost all adult patients in France aged 18-70 years and diagnosed with
      AML.

      FLT3 genetic alterations include FLT3 somatic point mutations within the second tyrosine
      kinase domain and internal duplications of the juxta-membrane domain. This alteration is
      refered to as FLT3-ITD. The FLT3-ITD mutation is found in around 30% of patients with
      cytogenetically normal AML. Patients with the FLT3-ITD genotype have been reported to have a
      poor outcome when treated with conventional chemotherapy with an estimated 4-year
      relapse-free survival of 25% (Schlenk et al. N Engl J Med 2008). More recently, the
      prognostic relevance of FLT3-ITD has been studied in the context of integrated genetic
      profiling. This confirmed the genetic complexity of AML and also that FLT3-ITD was
      associated with reduced overall survival in intermediate-risk AML. A multivariate analysis
      of several genetic alterations revealed that FLT3-ITD was the primary predictor of patient
      outcome. FLT3-ITD mutations were classified in 3 categories: 1) FLT3-ITD with +8, TET2,
      DNMT3A or MLL-PTD mutations (3-year OS 14.5%); 2) FLT3-ITD with wild type CEBPA, TET2, DNMT3
      and MLL-PTD (3-year OS 35.2%) and 3) FLT3-ITD with CEBPA mutations (3-year OS 42%) (Patel JP
      et al. N Engl J Med 2012). However, FLT3-ITD was not a predictor of response to induction
      therapy, allowing the introduction of targeted therapies after the induction course.

      Several FLT3 inhibitors have been evaluated or are currently being tested in the setting of
      relapsing AML. In most trials to date, patients were only eligible if the FLT3-ITD mutation
      was present. Disappointing results were reported with the first generation of FLT3
      inhibitors, including lestaurtinib (CEP-701), midostaurin (PKC-412) and sorafenib. Second
      generation FLT3 inhibitors such as quizartinib (AC220) are currently under investigation
      with promising results. However, the hematologic toxicity of AC220 will likely present a
      major limitation in evaluating AC220 combined with standard or high-dose chemotherapy.

      Ponatinib (AP24534) is a third generation tyrosine kinase inhibitor targeting the BCR-ABL
      tyrosine kinase domain. Ponatinib was rationally designed with an extensive network of
      optimized molecular contacts and triple bonds to accommodate the T315I mutation, a major
      cause of resistance to tyrosine kinase inhibitors in chronic and advanced phase chronic
      myelogenous leukemia (CML). Ponatinib also inhibits SRC (IC50: 5.4 nM) and members of the
      VEGFR, FGFR, and PDGFR families of receptor tyrosine kinases (O'Hare T, Cancer Cell 2009).
      Despite low activity against FLT3 based on the IC50 value (FLT3 IC50: 12.6 nM compared to
      BCR IC50: 0.37 nM), ponatinib has recently been reported to have significant cellular
      activity against the MV4-11 cell line which harbors an FLT3-ITD activating mutation.
      Ponatinib-induced apoptosis was maximal at 10 nM in vitro and a single dose of 5 and 10
      mg/kg had a strong inhibitory effect in vivo in mice bearing MV4-11 xenografts. Primary
      blast cells from 4 FLT3-ITD AML patients were also tested and ponatinib reduced their
      viability (IC50: 4 nM) whereas no activity was shown on FLT3-ITD-negative blast cells
      (Gozgit JM et al. Mol Cancer Ther 2011).

      Preliminary data from the phase I clinical trial showed that 15 mg ponatinib was associated
      with a Cmax of 51.1 nM. Cmax was increased to 111 nM and 149 nM in the 30 mg and 45 mg
      cohorts respectively. The trough concentrations were 55.3 nM and 61.9 nM for the 30 mg and
      45 mg doses respectively (Ariad clinical investigator's brochure, version 3). Results from
      the ongoing phase II trial in CML patients suggest that the hematological toxicity profile
      of ponatinib is comparable with that of nilotinib or dasatinib, both of which have been
      successfully combined with conventional chemotherapy.

      Investigators thus aim to combine ponatinib with cytarabine in FLT3-ITD AML patients in
      first complete remission.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose-limiting toxicity (DLT) of ponatinib during consolidation 1 with HDAC or IDAC</measure>
    <time_frame>12 months</time_frame>
    <description>assess the safety of increased doses of ponatinib in combination with high or intermediate -dose cytarabine in AML FLT3-ITD patients in first complete remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>To determine disease-free survival from achievement of first complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>To determine overall survival from achievement of first complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>To determine overall survival from diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease based on FLT3-ITD quantification, WT1 expression and/or NPM1 mutation quantification</measure>
    <time_frame>18 months</time_frame>
    <description>To study minimal residual disease after induction and consolidation courses based on the quantification of the FLT3-ITD signal and /or WT1, NPM if available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship between minimal residual disease and outcome</measure>
    <time_frame>18 months</time_frame>
    <description>To study the relationship between minimal residual disease and outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study ponatinib resistance mechanisms</measure>
    <time_frame>18 months</time_frame>
    <description>To assess FLT3-ITD mutant before and after ponatinib treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myeloid Lukemia</condition>
  <arm_group>
    <arm_group_label>Ponatinib arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose-escalation Arm _ 15, 30, 45mg Ponatinib per day. Each cohort will consist of 3 evaluable patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib and Cytarabine</intervention_name>
    <description>Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients</description>
    <arm_group_label>Ponatinib arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. a Patients aged 18 to 55-60 years: Cohort A b Patients aged 55-60 to 70 years: Cohort
             B

          2. Signed informed consent

          3. Acute myeloid leukemia in first complete remission

          4. Platelets ≥ 100 Giga/l; Neutrophils ≥ 1 Giga/l

          5. Intermediate risk karyotype with FLT3-ITD activating mutant detected at diagnosis
             (mutant FLT3/wild-type allelic ratio higher than 10%)

          6. Induction with intensive chemotherapy, dose dense sequential induction or 3 + 7 like
             regimen (daunorubicin or idarubicin) for Cohort A and inclusion in the ALFA backbone
             for cohort B (or 3 + 7 like regimen after approval of the study coordinator)

          7. Pancreatic functions within the normal range

          8. AST or ALT less or equal to 2.5 fold upper normal range, bilirubin less or equal to
             1.5 fold upper normal range

          9. Serum creatinine less or equal to 1.5 fold upper normal range

         10. Two planned consolidation courses with high-dose cytarabine (HDAC, Cohort A) or
             intermediate dose cytarabine (IDAC, Cohort B)

        Exclusion Criteria:

          1. Acute promyelocytic leukemia

          2. Inclusion in the ALFA 0702 trial

          3. Patient eligible for bone marrow transplant and with an identified donor

          4. Transformation of myeloproliferative or myelodysplastic syndromes

          5. Known central nervous system involvement.

          6. Uncontrolled bacterial, viral or fungal infection

          7. Other active malignancy

          8. Previous episode of pancreatitis

          9. Hypertriglyceridemia &gt; 4.5 g/L

         10. Lipase &gt; 1.5 × ULN, amylase &gt; 1.5 x ULN not related to leukemia

         11. QTc &gt; 470 ms (Bazett formula)

         12. Significant uncontrolled or active cardiovascular disease, specifically including,
             but not restricted to:

               -  Myocardial infarction, unstable angina and/or congestive heart failure within 3
                  months prior to randomization

               -  History of clinically significant (as determined by the treating physician)
                  atrial arrhythmia or any ventricular arrhythmia

               -  Uncontrolled hypertension

               -  Taking medications that are known to be associated with Torsades de Pointes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rousselot Philippe, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Versailles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morisset Laure</last_name>
    <phone>0033 1 39 23 97 85</phone>
    <email>lmorisset@ch-versailles.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MAROLLEAU Jean Pierre</last_name>
    </contact>
    <investigator>
      <last_name>MAROLLEAU Jean Pierre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital VICTOR DUPOUY</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AL JIJAKLI Ahmad</last_name>
      <email>ahmad.aljijakli@ch-argenteuil.fr</email>
    </contact>
    <investigator>
      <last_name>AL JIJAKLI Ahmad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Boulogne Sur Mer</name>
      <address>
        <city>Boulogne Sur Mer cedex</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHOUFI Bachra</last_name>
      <email>b.choufi@ch-boulogne.fr</email>
    </contact>
    <investigator>
      <last_name>CHOUFI Bachra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chr Clemenceau</name>
      <address>
        <city>Caen Cedex</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>REMAN Oumédaly</last_name>
      <email>reman-o@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>REMAN Oumédaly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PAUTAS Cécile</last_name>
      <email>cecile.pautas@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>PAUTAS Cécile</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CAILLOT Denis</last_name>
      <email>denis.caillot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>CAILLOT Denis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay cedex</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rousselot Philippe</last_name>
      <phone>003339638622</phone>
      <email>phrousselot@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Rousselot Philippe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>QUESNEL Bruno</last_name>
      <email>bquesnel@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>QUESNEL Bruno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Dupuytren</name>
      <address>
        <city>Limoges cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>TURLURE Pascal</last_name>
      <email>pascal.turlure@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>TURLURE Pascal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>THOMAS Xavier</last_name>
      <email>xavier.thomas@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>THOMAS Xavier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FRAYFER Jamilé</last_name>
      <email>j-frayfer@ch-meaux.fr</email>
    </contact>
    <investigator>
      <last_name>FRAYFER Jamilé</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice, Hôpital Archet 1</name>
      <address>
        <city>Nice cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MANNONE Lionel</last_name>
      <email>mannone.l@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>MANNONE Lionel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris cedex 12</city>
        <zip>75751</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ISNARD Françoise</last_name>
      <email>francoise.isnard@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>ISNARD Françoise</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris cedex 15</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SUAREZ Felipe</last_name>
      <email>felipe.suarez@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>SUAREZ Felipe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RAFFOUX Emmanuel</last_name>
      <email>emmanuel.raffoux@sls.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>RAFFOUX Emmanuel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UZUNOV Madalina</last_name>
      <email>madalina.uzunov@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>UZUNOV Madalina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Pontoise Cedex</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VAIDA Iona Dana</last_name>
      <email>ioana.vaida@ch-pontoise.fr</email>
    </contact>
    <investigator>
      <last_name>VAIDA Iona Dana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FERNANDES José</last_name>
      <email>fernandes-j@ch-valenciennes.fr</email>
    </contact>
    <investigator>
      <last_name>FERNANDES José</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 19, 2016</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Versailles</investigator_affiliation>
    <investigator_full_name>Philippe ROUSSELOT</investigator_full_name>
    <investigator_title>Clinical coordinator</investigator_title>
  </responsible_party>
  <keyword>FLT3-ITD patients in first complete remission</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
